Key result
Empagliflozin fails to reduce infarct size in non-diabetic rat hearts but improves post-ischemic mitochondrial respiration.
Why the study?
The mechanism by which the SGLT2-inhibitor empagliflozin reduces death from cardiovascular causes, specifically its direct protection against ischemia-reperfusion injury and effects on post-ischemic mitochondrial function, was unclear.
Does empagliflozin reduce infarct size and improve mitochondrial function in isolated perfused rat hearts subjected to ischemia-reperfusion injury?
Does empagliflozin reduce infarct size and improve mitochondrial function in isolated perfused rat hearts subjected to ischemia-reperfusion injury?
Answers are grounded in this paper and cite their sources.
Empagliflozin does not acutely reduce infarct size in non-diabetic rat hearts but modulates post-ischemic mitochondrial function, offering a potential mechanism for its long-term cardiovascular benefits.
Background: The Sodium Glucose Transporter 2 (SGLT2)-inhibitor, empagliflozin, reduces death from cardiovascular causes.We hypothesized that the mechanism involved direct protection against Ischemia-Reperfusion (IR) injury and improved post-ischemic mitochondrial function.Methods: We examined infarct size (series I) and mitochondrial respiration (series II) in four groups of isolated perfused hearts from male Wistar rats: Sham-operated hearts (Sham group), IR-injured hearts (IR group), hearts treated with ischemic preconditioning (IPC) by 2 × 5 min.cycles of IR prior to sustained ischemia (IPC group), and hearts co-perfused with 2.14 mg/l of empagliflozin 10 min.prior to sustained ischemia (EMPA group).Results: In contrast to IPC, empagliflozin did not reduce infarct size compared to the IR group, when given 10 min prior to the acute myocardial infarction.Empagliflozin improved post-ischemic complex I+II respiration compared to the IR group.This improvement was similar to IPC.In contrast to the improved complex I respiration by IPC, empagliflozin mainly improved complex II respiration.Empagliflozin hearts had significantly higher respiration in oligomycin induced state 4 than the sham and IR group, indicating that empagliflozin modulates the inner mitochondrial membrane. Conclusion:In conclusion, empagliflozin yielded no acute cardioprotection in the isolated perfused non-diabetic rat heart.Empagliflozin mainly improved complex II respiration and increased permeability of the inner membrane, providing a potential explanation for the positive long-term effects observed in post infarction myocardial dysfunction.
No takes yet. Share an insight, caveat, or question.
Jespersen et al. (2017) studied Acute Ischemic Reperfusion Injury (n=32). Empagliflozin vs. Ischemia-reperfusion (IR) control was evaluated on Infarct size. Empagliflozin did not reduce infarct size in isolated perfused non-diabetic rat hearts, but improved post-ischemic complex I+II mitochondrial respiration.
Synapse has enriched 10 related papers. Consider them for comparative context: